MarcoPolo Bio

MarcoPolo Bio is an early-stage biotechnology company focused on developing therapies that reprogram the innate immune system to combat cancer. The company specifically targets the tumor microenvironment by developing agents that can convert pro-tumor M2-like macrophages into anti-tumor M1-like macrophages, a process known as macrophage polarization. By reversing the immunosuppressive environment created by tumor-associated macrophages, MarcoPolo Bio aims to restore the body's ability to eliminate solid tumors. The company operates as part of the Curie.Bio portfolio, leveraging their specialized model to advance its pipeline of small molecule innate immune modulators toward clinical validation.